Akiyuki Suzuki

Learn More
We studied immunohistochemically the expression of beta-amyloid precursor protein (APP) in the frontal lobes of 18 Down syndrome (DS) patients (20 gestation weeks (GW) to 50 years) and 15 controls (17 GW to 50 years) using six purified antibodies against the secretory forms (N-terminal, N-Amy and Amy540), the Kunitz-type protease inhibitor (KPI) domain,(More)
BACKGROUND Axitinib is an oral, potent and selective inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3. We report on data obtained from 18 Japanese patients with advanced solid tumors in two phase I trials that evaluated the safety, pharmacokinetics and antitumor activity of axitinib and also examined potential biomarkers. (More)
Preclinical studies suggest that ALK-1 signaling mediates a complementary angiogenesis pathway activated upon development of resistance to vascular endothelial growth factor (VEGF)-targeted therapies. Inhibition of ALK-1 signaling may lead to disruption of tumor angiogenesis and growth. We report findings from a multicenter, open-label, phase I study of the(More)
We performed serial magnetic resonance imaging (MRI) toward 4 male children with possible Pelizaeus-Merzbacher disease (PMD). They were clinically suspected as PMD on the basis of typical neurological, electrophysiological and MRI examinations. MRI revealed that myelinated fibers were localized in brainstem, cerebellum, internal capsule, optic radiation and(More)
We present the brain autopsy and MRI findings in a four-year-old boy who was born at 23 weeks of gestational age and 700 gram of birthweight and experienced an episode of cardiac arrest at 10 months of age. Neuropathological study showed the findings compatible with cardiac arrest syndrome, the gliosis or neuronal loss of extensive cerebral lesions(More)
  • 1